Table 1:

Key features of 9 patients with radiologic ND-LCH disease

Patient	1	2	3	4	5	6	7	8	9
Sex	Male	Male	Female	Male	Male	Male	Male	Female	Female
Age at diagnosis of LCH	1 y 10 mo	2 y 9 mo	1 y 10 mo	3 y 4 mo	2 y	2 y 8 mo	16 y 10 mo	2 y 10 mo	6 mo
Organs involved at diagnosis of LCH	Bone, skin, liver, lung, spleen, hematopoietic system	Bone, skin	Bone, skin, liver	Bone, skin, DI	Bone, skin	Bone, skin, liver, spleen	Bone, skin, DI	Bone, skin, hematopoietic system, DI	Skin, liver
Course of LCH (outside the CNS)	Chronic active	3 RA	2 RA	no RA	4 RA	1 RA	2 RA	2 RA	Chronic active
Age at diagnosis of ND-LCH	6 y 6 mo	7 y 3 mo	5 y 7 mo	4 y 5 mo	2 y 6 mo	8 y 2 mo	17 y 11 mo	4 y 3 mo	4 y 3 mo
Interval diagnosis LCH to the diagnosis of ND	4 y 7 mo	4 y 7 mo	3 y 10 mo	1 y 1 mo	5 mo	5 y 7 mo	1y	1 y 5 mo	3 y 9 mo
MR imaging follow-up period	7 y 5 mo	10 y 3 mo	5 y 2 mo	7 y 6 mo	11 y	7 y 3 mo	5 y	11 y 8 mo	6 y 8 mo
No. of evaluated MR imaging studies	4	4	3	3	5	4	3	5	3
Age at last MR imaging	13 y 10 mo	17 y 6 mo	10 y 10 mo	11 y 8 mo	13 y 1 mo	15 y 5 mo	22 y 11 mo	15 y 10 mo	10 y 10 mo
Additional intracranial abnormalities
HPR abnormalities^**	−/+	+/+	+/+	+/+	−/+	+/+	+/+	+/+	+/+
Space-occupying meningeal lesions^**	−/−	−/+	−/−	−/−	−/+	−/−	−/−	+/+	−/−
Craniofacial bone lesions^**	+/+	+/+	+/+	+/−	+/+	+/−	+/+	+/+	−/−
Space-occupying intraparenchymal lesions^**	−/−	−/−	−/−	−/−	−/−	−/−	+/+	−/−	−/−
DI^*	−/+	+/+	−/+	+/+	−/+	+/+	+/+	+/+	+/+
Growth hormone deficiency^*	−/+	+/+	−/+	−/−	−/−	−/−	+/+	−/+	−/−
Neurologic symptoms^*	−/−	−/−	−/−	Ataxia/severe cerebellar symptoms	−/−	−/−	−/−	−/ataxia, spastic diplegia	−/−

Note:—ND indicates neurodegeneration; LCH, Langerhans cell histiocytosis; y, year; mo, month; DI, diabetes insipidus; RA, reactivation; HPR, hypothalamic pituitary region; −, absent; +, present.
* At diagnosis/at the last follow-up.
** before or at the diagnosis of ND-LCH/after the diagnosis of ND-LCH.